EGFR and non-small cell lung carcinoma: Inhibition of AKR1B1 restores sensitivity in EGFR TKI-resistant NSCLC cell lines with recognized resistance traits, including upregulation of AXL, activation of AKT and nuclear factor kB (NF-κB), and delayed acquired resistance in CDX and PDX mouse models24.